|
1.
|
|
14 p, 9.2 MB |
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
/
Ademà, Vera (The University of Texas MD Anderson Cancer Center) ;
Ma, Feiyang (University of Michigan) ;
Kanagal-Shamanna, Rashmi (The University of Texas MD Anderson Cancer Center) ;
Thongon, Natthakan (The University of Texas MD Anderson Cancer Center) ;
Montalban-Bravo, Guillermo (The University of Texas) ;
Yang, Hui (The University of Texas) ;
Peslak, Scott A. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Wang, Feng (The University of Texas MD Anderson Cancer Center) ;
Acha, Pamela (Universitat Autònoma de Barcelona) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lockyer, Pamela (The University of Texas MD Anderson Cancer Center) ;
Cassari, Margherita (University of Florence) ;
Maciejewski, Jaroslaw P. (Cleveland Clinic Foundation) ;
Visconte, Valeria (Cleveland Clinic Foundation) ;
Gañán-Gómez, Irene (The University of Texas MD Anderson Cancer Center) ;
Song, Yuanbin (Sun Yat-sen University Cancer Center) ;
Bueso-Ramos, Carlos (The University of Texas MD Anderson Cancer Center) ;
Pellegrini, Matteo (University of California) ;
Tan, Tuyet M. (Univerity of California San Diego) ;
Bejar, Rafael (Univerity of California San Diego) ;
Carew, Jennifer S. (University of Arizona Cancer Center) ;
Halene, Stephanie (Yale University School of Medicine) ;
Santini, Valeria (University of Florence) ;
Al-Atrash, Gheath (The University of Texas MD Anderson Cancer Center) ;
Clise-Dwyer, Karen (The University of Texas MD Anderson Cancer Center) ;
Garcia-Manero, Guillermo (The University of Texas MD Anderson Cancer Center) ;
Blobel, Gerd A. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Colla, Simona (The University of Texas MD Anderson Cancer Center)
SF3B1 -mutant MDS-RS is associated with buildup of erythroid progenitor cells upregulating EIF2AK1-associated heme deficiency response and autophagy genes. Targeting EIF2AK1 relieves the dysregulated progenitor phenotype. [...]
2022 -  10.1158/2643-3230.BCD-21-0220
Blood Cancer Discovery, Vol. 3 (august 2022) , p. 554-567
|
|
|
2.
|
|
15 p, 1.6 MB |
The ABNL-MARRO 001 study : a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
/
Moyo, Tamara K. (Vanderbilt University School of Medicine) ;
Mendler, Jason H (University of Rochester Medical Center) ;
Itzykson, Raphael (Paris Diderot University) ;
Kishtagari, Ashwin (Vanderbilt University School of Medicine) ;
Solary, Eric (Institut Gustave Roussy. Université Paris-Saclay) ;
Seegmiller, Adam C. (Vanderbilt University School of Medicine) ;
Gerds, Aaron T. (Cleveland Clinic) ;
Ayers, Gregory D. (Vanderbilt University School of Medicine) ;
Dezern, Amy E. (Johns Hopkins University) ;
Nazha, Aziz (Cleveland Clinic) ;
Valent, Peter (Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ;
Onida, Francesco (University of Milan) ;
Van Azizan de Loosdrecht, Arjan A. (Amsterdam UMC. University Medical Center) ;
Pleyer, Lisa (Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials) ;
Xicoy Cirici, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tibes, Raoul (Mayo Clinic) ;
Geissler, Klaus (Sigmund Freud University) ;
Komrokji, Rami S. (H. Lee Moffitt Cancer Center) ;
Zhang, Jing (University of Wisconsin-Madison) ;
Germing, Ulrich (Department of Hematology. Oncology. and Clinical Immunology. University of Duesseldorf) ;
Steensma, David P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Wiseman, Daniel H. (University of Manchester) ;
Pfeilstöecker, Michael (Hanusch Hospital and Ludwig Boltzmann Institute for Hematology and Oncology) ;
Elena, Chiara (University of Pavia) ;
Cross, Nicholas C P (University of Southampton) ;
Luebbert, Michael (University of Freiburg) ;
Mesa, Ruben A. (Mays Cancer Center at UT Health San Antonio MD Anderson) ;
Montalban-Bravo, Guillermo (MD Anderson Cancer Center) ;
Sanz, G.F. (Hospital Universitari i Politècnic La Fe (València)) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Patnaik, Mrinal M. (Mayo Clinic) ;
Padron, Eric (H. Lee Moffitt Cancer Center) ;
Santini, Valeria (University of Florence) ;
Fenaux, Pierre (Paris Diderot University) ;
Savona, Michael R. (Vanderbilt University School of Medicine) ;
Universitat Autònoma de Barcelona
Background: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and propensity of acute leukemic transformation, and have significant impact on patient quality of life. [...]
2022 - 10.1186/s12885-022-10073-w
BMC Cancer, Vol. 22 Núm. 1 (december 2022) , p. 1013
|
|
|
3.
|
|
9 p, 1.9 MB |
Clinical consequences of BRCA2 hypomorphism
/
Castells-Roca, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Gutiérrez-Enríquez, Sara (Vall d'Hebron Institut d'Oncologia) ;
Bonache, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Bogliolo, Massimo (Institut d'Investigació Biomèdica Sant Pau) ;
Carrasco, E. (Vall d'Hebron Institut d'Oncologia) ;
Aza-Carmona, Miriam (Institut d'Investigació Biomèdica Sant Pau) ;
Montalban, G. (CHU de Québec - Université Laval Research Center. Oncology division) ;
Muñoz-Subirana, N. (Institut d'Investigació Biomèdica Sant Pau) ;
Pujol, Roser (Institut d'Investigació Biomèdica Sant Pau) ;
Cruz Zambrano, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Llop-Guevara, A. (Vall d'Hebron Institut d'Oncologia) ;
Ramírez de Haro, Ma. José (Institut d'Investigació Biomèdica Sant Pau) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Lasa, Adriana (Institut d'Investigació Biomèdica Sant Pau) ;
Serra, V. (Vall d'Hebron Institut d'Oncologia) ;
Diez, Orland (Vall d'Hebron Institut d'Oncologia) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Surrallés i Calonge, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. [...]
2021 - 10.1038/s41523-021-00322-9
NPJ breast cancer, Vol. 7 Núm. 1 (december 2021) , p. 117
|
|
|
4.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, Marta (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, Sara (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y. H. (Experimental Therapeutics Group) ;
Gris-Oliver, Albert. (Experimental Therapeutics Group) ;
Bonache, Sandra (Oncogenetics Group) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O. M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U. M. (Cancer Research UK. Cambridge Institute) ;
Jones, G. N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzmán, Marta (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, Judit (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratù, Ginevra (Cancer Genomics Group) ;
Mancuso, Francesco M (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W. J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ;
Oaknin, Ana (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J. Carl (AstraZeneca (USA)) ;
Caldas, Carlos (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ;
Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Jonkers, Jos (Cancer Genomics Group) ;
Diez, Orland (Hospital Universitari Vall d'Hebron) ;
O'Connor, M. J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
